Statins and Dementia

Peter discusses the complexities surrounding Parkinson's disease literature and highlights surprising findings regarding statins, revealing no significant difference in outcomes between hydrophobic and hydrophilic types. He notes atorvastatin's higher diabetes risk, while emphasizing the importance of monitoring side effects in individual patients. Additionally, a recent internal presentation explored the link between statin use, desmosterol levels, and dementia risk.